In a Phase II study on 119 patients with advanced ovarian cancer in which the standard therapies had already been ineffective, treatment with abagovomab led to a prolongation of survival time (23.4 months compared to 4.9 months) in those patients who responded to the vaccination, i.e.
A Phase II clinical test on 119 ovarian cancer patients who had not responded to standard therapies revealed that abagovomab therapy significantly prolonged their survival period (23.4 months versus 4.9 months), particularly in those who reacted positively to the vaccine.